Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Ephedra safety study

This article was originally published in The Tan Sheet

Executive Summary

Acute phase results from industry-sponsored research will be available Nov. 1 "at the latest," the Ephedra Research Foundation tells FDA June 12; the study is under way at Beth Israel-Deaconess Medical Center (Boston) and St. Luke's-Roosevelt Hospital (New York City). Results initially were expected to be ready May 1. The foundation requests FDA "delay the issuance of any final rule or guidance document" on ephedra as a dietary supplement ingredient, until the agency has reviewed results of the acute phase. As of May 31, 69 of 150 subjects had completed the acute phase in which mildly to severely overweight subjects are administered medication containing ephedra alkaloids and caffeine and are monitored for blood pressure increase, heart rate and prevalence of arrhythmia ("The Tan Sheet" Dec. 8, 1997, p. 20)...
Advertisement
Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

PS088642

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel